对抗耐抗生素淋病可带来潜在的健康和经济效益图示。
An Illustration of the Potential Health and Economic Benefits of Combating Antibiotic-Resistant Gonorrhea.
机构信息
From the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
出版信息
Sex Transm Dis. 2018 Apr;45(4):250-253. doi: 10.1097/OLQ.0000000000000725.
Abstract
Preventing the emergence of ceftriaxone-resistant Neisseria gonorrhoeae can potentially avert hundreds of millions of dollars in direct medical costs of gonorrhea and gonorrhea-attributable HIV infections. In the illustrative scenario we examined, emerging ceftriaxone resistance could lead to 1.2 million additional N. gonorrhoeae infections within 10 years, costing $378.2 million.
摘要
预防头孢曲松耐药淋病奈瑟菌的出现，可能避免因淋病和淋病相关的 HIV 感染而产生数亿美元的直接医疗费用。在我们研究的说明性情景中，新出现的头孢曲松耐药性可能导致未来 10 年内新增 120 万例淋病奈瑟菌感染，花费 3.782 亿美元。
相似文献
1
An Illustration of the Potential Health and Economic Benefits of Combating Antibiotic-Resistant Gonorrhea.对抗耐抗生素淋病可带来潜在的健康和经济效益图示。
Sex Transm Dis. 2018 Apr;45(4):250-253. doi: 10.1097/OLQ.0000000000000725.
2
Ceftriaxone-resistant Neisseria gonorrhoeae, Japan.日本的耐头孢曲松淋病奈瑟菌
Emerg Infect Dis. 2011 Jan;17(1):148-9. doi: 10.3201/eid1701.100397.
3
[Antibiotic susceptibility of Neisseria gonorrhoeae in Guadalajara area].[瓜达拉哈拉地区淋病奈瑟菌的抗生素敏感性]
Rev Esp Quimioter. 2011 Mar;24(1):48-9.
4
Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014.淋病奈瑟菌抗菌药物敏感性监测 - 淋球菌分离株监测项目，美国 27 个监测点，2014 年。
MMWR Surveill Summ. 2016 Jul 15;65(7):1-19. doi: 10.15585/mmwr.ss6507a1.
5
Trends in antimicrobial resistance in Neisseria gonorrhoeae in Hanoi, Vietnam, 2017-2019.2017-2019 年越南河内淋病奈瑟菌的抗生素耐药趋势。
BMC Infect Dis. 2020 Nov 5;20(1):809. doi: 10.1186/s12879-020-05532-3.
6
Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin.对头孢曲松和阿奇霉素均耐药的淋病奈瑟菌的基因特征分析
Lancet Infect Dis. 2018 Jul;18(7):717-718. doi: 10.1016/S1473-3099(18)30340-2.
7
CDC update on gonorrhea: expand treatment to limit resistance.美国疾病控制与预防中心关于淋病的最新情况：扩大治疗范围以限制耐药性。
J Fam Pract. 2011 Dec;60(12):736-40.
8
Identification of Internationally Disseminated Ceftriaxone-Resistant Neisseria gonorrhoeae Strain FC428, China.鉴定具有国际传播性的耐头孢曲松淋病奈瑟菌 FC428 株，中国。
Emerg Infect Dis. 2019 Jul;25(7):1427-1429. doi: 10.3201/eid2507.190172. Epub 2019 Jul 17.
9
Neisseria gonorrhoeae Resistant to Ceftriaxone and Cefixime, Argentina.阿根廷发现对头孢曲松和头孢克肟耐药的淋病奈瑟菌
Emerg Infect Dis. 2016 Jun;22(6):1139-41. doi: 10.3201/eid2206.152091.
10
Emergence of Extensively Drug-Resistant Neisseria gonorrhoeae, France, 2023.2023 年法国出现了广泛耐药淋病奈瑟菌。
Emerg Infect Dis. 2024 Sep;30(9):1903-1906. doi: 10.3201/eid3009.240557. Epub 2024 Jul 31.
引用本文的文献
1
Antimicrobial Resistance in Curable Sexually Transmitted Infections.可治愈性传播感染中的抗菌药物耐药性
Curr HIV/AIDS Rep. 2025 Jan 25;22(1):14. doi: 10.1007/s11904-025-00722-7.
2
Vaccine value profile for Neisseria gonorrhoeae.淋病奈瑟菌疫苗的价值概况。
Vaccine. 2024 Jul 25;42(19S1):S42-S69. doi: 10.1016/j.vaccine.2023.01.053. Epub 2023 Dec 13.
3
Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study.可治愈性传播感染中抗菌药物耐药性的经济评价：系统评价和案例研究。
PLoS One. 2023 Oct 19;18(10):e0292273. doi: 10.1371/journal.pone.0292273. eCollection 2023.
4
Rapid molecular phenotypic antimicrobial susceptibility test for based on propidium monoazide viability PCR.基于单叠氮碘化丙啶活菌PCR的快速分子表型抗菌药敏试验。
bioRxiv. 2023 Mar 1:2023.03.01.530513. doi: 10.1101/2023.03.01.530513.
5
Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics.纳米技术作为对抗微生物的新方法：提供抗生素的替代方案
Antibiotics (Basel). 2021 Nov 30;10(12):1473. doi: 10.3390/antibiotics10121473.
6
Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea.用于控制和预防性传播疾病淋病的候选疫苗
Vaccines (Basel). 2021 Jul 20;9(7):804. doi: 10.3390/vaccines9070804.
7
Systematic Literature Review and Quantitative Analysis of Health Problems Associated with Sexually Transmitted Neisseria gonorrhoeae Infection.与性传播淋病奈瑟菌感染相关健康问题的系统文献综述与定量分析
Infect Dis Ther. 2021 Dec;10(4):1887-1905. doi: 10.1007/s40121-021-00481-z. Epub 2021 Jul 17.
8
A profile of the binx health ® molecular point-of-care test for chlamydia and gonorrhea in women and men.关于 binx health ® 分子即时检测试剂盒用于女性和男性沙眼衣原体和淋病的简介。
Expert Rev Mol Diagn. 2021 Sep;21(9):861-868. doi: 10.1080/14737159.2021.1952074. Epub 2021 Jul 12.
9
The Estimated Number and Lifetime Medical Cost of HIV Infections Attributable to Sexually Transmitted Infections Acquired in the United States in 2018: A Compilation of Published Modeling Results.2018 年美国性传播感染导致的艾滋病毒感染预估数量和终身医疗费用：已发表模型研究结果汇编。
Sex Transm Dis. 2021 Apr 1;48(4):292-298. doi: 10.1097/OLQ.0000000000001358.
10
Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019.淋球菌疫苗：公共卫生价值和首选产品特征；世卫组织全球利益攸关方协商会议报告，2019 年 1 月。
Vaccine. 2020 Jun 9;38(28):4362-4373. doi: 10.1016/j.vaccine.2020.02.073. Epub 2020 Apr 28.
本文引用的文献
1
Antiretroviral Therapy for the Prevention of HIV-1 Transmission.抗逆转录病毒疗法预防HIV-1传播
N Engl J Med. 2016 Sep 1;375(9):830-9. doi: 10.1056/NEJMoa1600693. Epub 2016 Jul 18.
2
Antibiotic-Resistant Neisseria gonorrhoeae Spread Faster with More Treatment, Not More Sexual Partners.耐抗生素淋病奈瑟菌通过更多治疗而非更多性伴侣传播得更快。
PLoS Pathog. 2016 May 19;12(5):e1005611. doi: 10.1371/journal.ppat.1005611. eCollection 2016 May.
3
No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting.在临床实践环境中，随着艾滋病病毒暴露前预防措施使用的增加，新的艾滋病病毒感染病例未出现增长。
Clin Infect Dis. 2015 Nov 15;61(10):1601-3. doi: 10.1093/cid/civ778. Epub 2015 Sep 1.
4
Public health measures to control the spread of antimicrobial resistance in Neisseria gonorrhoeae in men who have sex with men.控制男男性行为者中淋病奈瑟菌抗菌药物耐药性传播的公共卫生措施。
Epidemiol Infect. 2015 Jun;143(8):1575-84. doi: 10.1017/S0950268814002519. Epub 2014 Oct 2.
5
Ciprofloxacin resistance and gonorrhea incidence rates in 17 cities, United States, 1991-2006.1991 - 2006年美国17个城市的环丙沙星耐药性与淋病发病率
Emerg Infect Dis. 2014 Apr;20(4):612-9. doi: 10.3201/eid2004.131288.
6
Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era.检测与治疗时代艾滋病预防所节省的终生成本及质量调整生命年。
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):e15-8. doi: 10.1097/QAI.0b013e3182a5c8d4.
7
The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008.美国 2008 年部分性传播感染疾病的直接医疗费用估算。
Sex Transm Dis. 2013 Mar;40(3):197-201. doi: 10.1097/OLQ.0b013e318285c6d2.
8
Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008.美国男女人群中的性传播感染：2008 年的流行率和发病率估计。
Sex Transm Dis. 2013 Mar;40(3):187-93. doi: 10.1097/OLQ.0b013e318286bb53.
9
Core groups, antimicrobial resistance and rebound in gonorrhoea in North America.核心群组、耐抗菌药物淋病和淋病在北美的反弹。
Sex Transm Infect. 2012 Apr;88(3):200-4. doi: 10.1136/sextrans-2011-050049. Epub 2011 Dec 14.
10
Gonococcal resistance: are cephalosporins next?淋球菌耐药性：头孢菌素类药物会是下一个吗？
Curr Infect Dis Rep. 2011 Apr;13(2):196-204. doi: 10.1007/s11908-011-0169-9.
Zotero 插件